Informes de Analista

RMD RMD

2026-08-20

MUESTRA — de hace 1 semana

Este es un informe de muestra. Desbloquea Premium para ver los informes más recientes y la biblioteca completa.

Resumen ejecutivo

ResMed (RMD) presents a mixed picture: its profitability metrics improved meaningfully in FY2026, with net income rising 8.8% to 1,523.29M USD and cash increasing 21.5% to 1,469.23M USD. At the same time, equity grew 10.3% and shares outstanding fell 1.5%, pointing to disciplined capital allocation and buybacks. Despite this fundamental strength, the stock has declined 20.2% over the last year, closing at 230.65 USD in August 2026 after a volatile two-year period.

Veredicto

Infravalorada

Evolución bursátil (2 años)

From August 2024 to August 2026, RMD delivered a total return of +3.4%, moving from 223.15 to 230.65 USD. The path was volatile: the price peaked at 293.73 and bottomed at 182.82. In the last 12 months, the stock lost 20.2%, with a sharp decline from around 255 in late 2025 to a low of 192.91 in July 2026, followed by a recent rebound to 226.74 on August 13 and a 4.8% rally reported in mid-August 2026.

Catalizadores futuros

▸Continued share buybacks reducing outstanding shares
▸Further margin expansion as operating leverage improves
▸Potential market re-rating after recent news highlighting 31-32% undervaluation
▸Strong cash position could support strategic investments or dividends

Riesgos clave

▸Soft FY27 outlook mentioned in recent news could pressure growth expectations
▸Lack of revenue data reduces visibility on top-line momentum
▸Debt levels are unknown, limiting full balance sheet assessment
▸Competitive and regulatory pressures in the medical device sector

Drivers financieros clave

Fundamental drivers include a steady increase in net income (from 1,400.72M to 1,523.29M, +8.8%), improved gross and operating margins in absolute terms, higher cash reserves (+21.5%), and a growing equity base (+10.3%). The reduction in shares outstanding (-1.5%) is consistent with an active buyback program. However, revenue figures were not provided, so margin ratios based on revenue could not be calculated.

Solo informativo — no es asesoramiento de inversión.

¿Quieres un resumen diario gratuito de la actividad de insiders? Suscríbete: